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Did Large-Scale Vaccination 
Drive Changes in the Circulating 
Rotavirus Population in Belgium?
Virginia E. Pitzer1,2, Joke Bilcke3, Elisabeth Heylen4, Forrest W. Crawford5, Michael Callens6, 
Frank De Smet6,7, Marc Van Ranst4, Mark Zeller4 & Jelle Matthijnssens4
Vaccination can place selective pressures on viral populations, leading to changes in the distribution 
of strains as viruses evolve to escape immunity from the vaccine. Vaccine-driven strain replacement 
is a major concern after nationwide rotavirus vaccine introductions. However, the distribution of the 
predominant rotavirus genotypes varies from year to year in the absence of vaccination, making it 
difficult to determine what changes can be attributed to the vaccines. To gain insight in the underlying 
dynamics driving changes in the rotavirus population, we fitted a hierarchy of mathematical models 
to national and local genotype-specific hospitalization data from Belgium, where large-scale 
vaccination was introduced in 2006. We estimated that natural- and vaccine-derived immunity was 
strongest against completely homotypic strains and weakest against fully heterotypic strains, with an 
intermediate immunity amongst partially heterotypic strains. The predominance of G2P[4] infections in 
Belgium after vaccine introduction can be explained by a combination of natural genotype fluctuations 
and weaker natural and vaccine-induced immunity against infection with strains heterotypic to the 
vaccine, in the absence of significant variation in strain-specific vaccine effectiveness against disease. 
However, the incidence of rotavirus gastroenteritis is predicted to remain low despite vaccine-driven 
changes in the distribution of genotypes.
Rotavirus gastroenteritis (RVGE) is estimated to kill more than 450,000 children below the age of 5 years annually1. 
Since 2009 the WHO has recommended the inclusion of rotavirus vaccines in national immunization sched-
ules worldwide2. Currently two live, oral rotavirus vaccines, Rotarix® (GlaxoSmithKline Biologicals, Rixensart, 
Belgium) and RotaTeq® (Merck and Co., Whitestation, NJ, USA), are licensed in most countries around the world3.
Group A Rotaviruses (RVAs) are double-stranded RNA viruses with a genome composed of 11 segments4,5. 
While a large diversity of RVA strains has been described in literature, only two major RVA genotype constellations 
(Wa-like and DS-1-like) are known to cause the vast majority of RVGE in humans. Despite the rather conserved 
nature of these human RVA genomes, the two outer capsid proteins, VP7 and VP4, are much more variable in 
comparison with the rest of the genome6. These two outer capsid proteins both elicit neutralizing antibodies, and are 
classified into distinct G- (VP7) and P- (VP4) genotypes7,8. In high-income countries, the DS-1-like human RVAs 
are usually found in combination with G2 and P[4], whereas the Wa-like human RVA strains are usually found 
in combination with G1, G3, G4, G9, G12 and P[8]6,9–18. Human RVAs with various G/P-genotype combinations 
are known to co-circulate in any given location at any given time, and strong fluctuations in their distributions are 
known to occur from year to year and from one location to another19. Currently, the reasons for these fluctuations 
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are poorly understood, although homotypic and heterotypic immunity due to natural RVA exposure or vaccination 
are believed to play important roles, in addition to several other stochastic factors20.
Rotavirus vaccines, available since 2006, have been successful at controlling the burden of RVGE in countries 
with large-scale vaccination programs. The two available vaccines differ in their approach to eliciting immunity21. 
The Rotarix vaccine consists of an attenuated Wa-like G1P[8] RVA strain, whereas RotaTeq contains a cocktail of 
5 bovine RVA strains (distinct from the typical human Wa- and DS-1-like RVA strains), where each strain contains 
either a human VP7 (G1, G2, G3 and G4) or VP4 (P[8]) gene, introduced by in vitro reassortment22. Although there 
is a broad scientific consensus that both vaccines are highly effective in reducing the burden of severe RVGE, there 
is still controversy regarding the long-term effects of vaccination on the circulating RVA genotype distribution20,23. 
Changes in the genotype distribution have been observed following large-scale vaccination with Rotarix and/or 
RotaTeq in the United States, some Australian states, and Brazil20,24–27, but it remains unclear if these changes can 
be attributed to vaccination. In Belgium, where primarily Rotarix is used, a clear increase in the proportion of 
RVGE cases caused by the G2P[4] genotype was noted after vaccine introduction, and has lasted now for at least 
7 seasons (2006–2013)28,29 [unpublished data]. In addition, a recent study found strong statistical differences in 
the genotype distribution of vaccinated and unvaccinated children, with an increased prevalence of G2P[4] in 
vaccinated children in Belgium, suggesting that Rotarix may exert selective pressures on the viral population30.
Mathematical models can provide insight into the underlying dynamics of rotavirus and changing rotavirus 
populations. However, ours is the only model thus far to have explicitly accounted for the interaction of multiple 
strains of rotavirus that co-circulate31. Moreover, very few rotavirus models have been fitted to post-vaccination 
data32. The lack of strain-specific rotavirus models may be due to uncertainties in the many parameters needed 
to describe the interaction of different strains and the difficulties associated with fitting complex epidemiological 
models to data. The one strain-specific model for rotavirus demonstrated that the cycling of genotypes in the pop-
ulation could be explained by differences in homotypic and heterotypic immunity, and predicted that vaccination 
with a monovalent vaccine such as Rotarix could exert different pressures on the viral population than a vaccine that 
provided strong protection again all strains, such as RotaTeq31. However, the model did not differentiate between 
Wa-like and DS-1-like rotavirus strains and the differences in immunity that may result.
Here, we utilize mathematical models to explore the hypothesis that selection pressures imposed by large-scale 
rotavirus vaccination can explain the observed impact of vaccination and changes to the genotype distribution 
in Belgium. We employ a hierarchy of models fit to multiple sources of data to estimate key parameters to refine 
model predictions for the long-term impact of vaccination and to explain the predominance of G2P[4] following 
vaccine introduction in Belgium.
Results
Impact of vaccination on the overall incidence of RVGE. Observed impact. Rotavirus vaccination 
coverage with at least one dose increased from 0% to 75% during 2006, and the coverage with either vaccine has 
levelled off at approximately 86% (Fig. 1a,b, Fig. S1); however, only 79% of infants received a full course of either 
vaccine in 2012 (Fig. 1a, Fig. S1). Since the start of vaccination, the number of rotavirus related hospitalizations 
recorded by Carenet-NCSF has decreased by 85% (Fig. 1a). The largest decrease occurred in patients < 2 years 
of age (67%, Fig. 1c,d). A more detailed description of the overall impact of vaccination on rotavirus burden in 
Belgium can be found in a separate paper33.
Predicted impact. Our non-strain-specific model (Fig. 2a) was able to provide a good fit to the Carenet-NCSF 
data, although there was a tendency to slightly overestimate the peak number of rotavirus hospitalizations recorded 
during the 2006/07 season (Fig. 1b). The model was able to capture the age distribution of hospitalized cases well 
for children 1–4 years old, but slightly overestimated the proportion of hospitalizations in infants < 6 months of 
age and underestimated the proportion of cases in 6–11 month olds both before and after vaccine introduction, 
and overestimated the proportion of cases among ≥ 5 year olds following vaccine introduction (Fig. 1c,d).
Parameter estimates. A variety of estimated parameter combinations were able to provide a good fit to the 
Carenet-NCSF data, both visually (Fig. 1) and statistically as indicated by comparing the log posterior probability (up 
to a normalizing constant) of the fitted models (Table 1). Estimates of the basic reproductive number, R0 (an impor-
tant measure of transmissibility, defined as the expected number of secondary infections generated by one infectious 
individual in a fully susceptible population) varied from 13.6 to 21.6, and were negatively correlated with esti-
mates of the relative infectiousness of asymptomatic infections (Pearson’s r = − 0.98, p < 0.0001) (Table 1, Fig. S2). 
Most models estimated that ~50% of moderate-to-severe RVGE cases result in hospitalization with a rotavirus 
diagnosis among children < 2 years old; reporting rates were estimated to be 69–85% lower among older children 
and adults, for whom the cost of rotavirus testing is not reimbursed (Table 1).
Model validation. We validated the non-strain-specific model by comparing to the hospitalization data from 
Gasthuisberg University Hospital (GUH) in Leuven, Belgium. The fitted models were able to capture both the size 
and timing of the rotavirus epidemic in most years, including the pre- and post-vaccination years not included 
in the Carenet-NCSF data (1993–2004, 2012–2013). However, we were not able to explain all of the year-to-year 
variability (e.g. the large peak in 1997/98 or the early activity in 1998/99) (Fig. 3a). Estimates of the reporting rate 
varied from 0.0155 to 0.0176 (Table 1). The models also provided a reasonably good fit to the age distribution of 
RVGE hospitalized cases (which included more detailed age classes than the data used for model fitting), although 
they tended to underestimate the post-vaccination number of hospitalizations in 2–15 month olds and overestimate 
the hospitalizations in the < 2 month and ≥ 5 year age groups (Fig. 3b,c).
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Impact of vaccination on the distribution of rotavirus genotypes. Observed impact. There 
were a mean of 158 (range: 112–215) RVGE hospitalizations per year that were identified and typed at GUH in 
Leuven prior to vaccine introduction (Fig. 4a). On average 40% of these were G1, although this proportion varied 
from 8% (in 2002/03) to 74% (in 1999/00) (Fig. 4b). G9 was the second most prevalent G-type prior to vaccine 
introduction, responsible for 29% of hospitalizations overall (annual range: 4%–52%), while G2 was responsi-
ble for < 18% of hospitalizations in any given year (6% overall) (Fig. 4b,c). Since January 2006, vaccination has 
been occurring primarily with the Rotarix (RV1) vaccine; coverage with RotaTeq (RV5) peaked at 19% in June 
2010 (Fig. 4a). Following vaccine introduction, the proportion of hospitalizations due to G1 decreased to 28% 
overall in Leuven (range: 8–47%), while the proportion due to G2 jumped to 39% overall and 77% in 2012/13 
(Fig. 4b,c). The post-vaccination genotype distribution for Belgium as a whole (based on data from the Rotavirus 
Surveillance Network Belgium (RSNB)) was similar (Fig. 4c). Other G-types (e.g. G12) accounted for < 1% of all 
typed samples (Fig. 4c).
Parameter estimates. We estimated that heterotypic immunity (σ
HE = 0.95, 95% credible interval (CI): 0.77–1.00) 
was considerably weaker than homotypic immunity (σ
HO  = 0.41, 95% CI: 0.20–0.62), while immunity against 
partially heterotypic strains was intermediate (σ
PH  = 0.78, 95% CI: 0.65–0.91) (Fig. 5a). Both non-G1 P[8] strains 
(G3P[8], G4P[8] and G9P[8]) (r1 = 0.97, 95% CI: 0.95–1.00) and G2P[4] strains (r2 = 0.92, 95% CI: 0.88–0.99) 
were estimated to be slightly less transmissible than G1P[8] strains (Fig. 5b), which helps explain the predominance 
of G1P[8] prior to vaccine introduction31, although the 95% credible interval for the relative transmissibility of 
non-G1P[8] strains includes 1. Vaccination (with either vaccine) was estimated to generate a broadly heterotypic 
immune response in 94% (95% CI: 81–99%) of vaccinees (Fig. 5c). As such, the modelled vaccine effectiveness of 
RV1 against homotypic G1P[8] strains (VERV1,HO = 97.2%, 95% CI: 94.7–98.4%) versus partially heterotypic G3P[8], 
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Figure 1. Rotavirus hospitalizations in Belgium from July 2004 to June 2012. (a) Number of weekly 
hospitalizations with a rotavirus diagnosis reported in the Carenet-NCSF database (blue) is plotted along 
with the proportion of the Belgian population who receive their health insurance through NCSF (green) and 
the proportion of hospital beds included in the Carenet database (red). The interpolated weekly vaccination 
coverage with at least one dose is indicated by the dashed black line. (b) The output of the non-strain-specific 
models fit to the Carenet-NCSF data is plotted in grey, while the number of weekly rotavirus gastroenteritis 
(RVGE) hospitalizations reported in Carenet-NCSF (blue) and vaccination coverage (dashed black line) 
are plotted as above. (c) The age distribution of rotavirus hospitalizations in Carenet-NCSF prior to vaccine 
introduction (July 2004-June 2006) is indicated by the blue bars, while the grey bars represent the mean of the 
fitted models. The black error bars represent the range of the fitted models. (d) The age distribution of rotavirus 
hospitalizations after vaccine introduction (July 2006-June 2012) for the Carenet-NCSF data (blue) and the 
fitted models (grey).
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G4P[8], and G9P[8] strains (VERV1,PH = 95.1%, 95% CI: 90.9–97.1%) or fully heterotypic G2P[4] strains 
(VERV1,HE = 93.7%, 95% CI: 88.3–96.9%) did not vary substantially, and are similar to estimates of genotype-specific 
vaccine effectiveness from Belgium29,30. The modelled vaccine effectiveness for RV5 was similar albeit slightly 
higher (VERV5 = 98.5%, 95%CI: 96.6–99.6%).
Predicted impact. These slight differences in immunity could explain the observed genotype patterns, includ-
ing the increase in the proportion of RVGE hospitalizations caused by G2P[4] following vaccine introduction 
in Belgium (Fig. 6). The best-fit model was able to reproduce both the pre- and post-vaccination incidence of 
hospitalization for RVGE in Leuven, as well as the pre-vaccination distribution of genotypes in Leuven and the 
post-vaccination genotype distribution throughout Belgium (Fig. 6). When we sampled at random (without 
replacement) from the joint posterior distribution of the estimated parameters, all of the simulated models were 
able to capture the epidemic trajectories as well as differences between the pre- and post-vaccination genotype dis-
tributions (Fig. 6). However, the models had a tendency to slightly underestimate the size of epidemics in 2007/08, 
as well as some of the pre-vaccination seasons, while overestimating the size of other pre-vaccination epidemics 
(Fig. 6a). Furthermore, some models tended to slightly overestimate the proportion of cases due to G3P[8] and 
G4P[8] and slightly underestimate the proportion due to G9P[8] prior to vaccine introduction, whereas following 
vaccine introduction, the proportion of cases due to G1P[8] was slightly underestimated in some models and 
overestimated in others (Fig. 6b,c). It is likely that some of these discrepancies may be due to stochastic effects, 
which we do not account for in our model.
The best-fit model reproduces the observed cyclical pattern in the distribution of genotypes, although the 
timing of the cycles varies somewhat from the observed pattern (Fig. 7a). If vaccination coverage remains at the 
most recently observed levels, our model predicts that G2P[4] will remain the predominant genotype for another 
year or two at most, after which one or more of the non-G1 P[8] strains may predominate for a number of years 
(Fig. 7a). The prevalence of G1P[8] strains is predicted to decline to negligible levels in the near future, and the 
overall incidence of RVGE is expected to remain low (Fig. 7a). In the absence of vaccination, our model predicted 
that the incidence of RVGE would continue at the pre-vaccination levels, as would the cycling of genotypes, such 
that the average genotype distribution would remain similar to the pre-vaccination distribution over the 7-year 
timeframe between July 2006 and June 2013 (Fig. 7b). If vaccination were to stop in July 2015, the incidence of 
RVGE is expected to rebound to pre-vaccination levels within two years, and G1P[8] is expected to re-emerge as 
the predominant strain within five years (Fig. 7c). If coverage were to increase to 100% with at least two doses of 
the vaccines, the incidence of RVGE is expected to decline to very low levels, with < 500 hospitalizations per year 
in Belgium (Fig. 7d). Finally, if vaccination were to continue at current levels overall, but market shares of Rotarix 
and RotaTeq were to switch such that 90% of all vaccines administered were RotaTeq, the incidence of RVGE would 
remain similar to the current post-vaccination levels, but G1P[8] would be expected to become the predominant 
strain within a few years (Fig. 7e).
Discussion
This is the first study to use a mechanistic model of vaccine impact to show that observed changes in the rotavirus 
genotype distribution in Belgium, in particular the prolonged increased prevalence of G2P[4] strains, can be 
Figure 2. Compartmental diagrams illustrating model structures. (a) Non-strain-specific model. (b) Strain-
specific model. Symbols are explained in the Methods section.
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Parameter Symbol
Initial 
range Prior dist-ribution
Model 
1
Model 
2
Model 
3
Model 
4
Model 
5
Model 
6
Model 
7
Model 
8
Model 
9
Model 
10
Basic reproductive number R0 = β0/γ 15 to 30 U (5,30) 20.0 17.3 15.5 19.5 15.1 20.9 13.6 21.6 17.3 15.8
Relative infectiousness of 
mild/asymptomatic infections ρA 0.1 to 0.3 U (0,0.5) 0.16 0.19 0.23 0.16 0.24 0.11 0.29 0.12 0.19 0.23
Amplitude of seasonality in 
transmission b 0.05 to 0.1 U (0,0.3) 0.095 0.086 0.084 0.094 0.085 0.089 0.081 0.095 0.086 0.084
Seasonal offset φ − 0.03 to 0.07 years U (− 0.5,0.5) − 0.022 0.020 0.011 0.008 − 0.028 0.015 0.008 − 0.004 0.009 0.005
Duration of temporary 
immunity 1/ω
26 to 39 
weeks U (26,52) 28.4 32.4 31.3 31.4 26.5 30.5 30.9 31.9 35.0 35.9
Proportion of vaccinees 
receiving protection equal to 
two natural infections
ξ 0.2 to 0.8 U (0,1) 0.48 0.59 0.37 0.90 0.71 0.29 0.85 0.43 0.89 0.98
Hospitalization/reporting rate 
among < 2 year olds h0 0.48 to 0.52 U (0,1) 0.52 0.51 0.43 0.50 0.48 0.50 0.44 0.52 0.55 0.53
Relative rate of hospitalization 
among ≥ 3 year olds η 0.2 to 0.6 U (0,1) 0.28 0.20 0.21 0.23 0.23 0.20 0.25 0.31 0.15 0.15
Log posterior − 5,191 − 5,290 − 5,218 − 5,112 − 5,243 − 5,366 − 5,236 − 5,191 − 5,137 − 5,098
Model validation
  Hospitalization/reporting 
rate among < 2 year olds 
at GUH
hG NA U (0,1) 0.0155 0.0168 0.0164 0.0163 0.0164 0.0171 0.0163 0.0155 0.0176 0.0175
 Log posterior − 7,288 − 7,267 − 7,271 − 7,273 − 7,271 − 7,265 − 7,273 − 7,287 − 7,264 − 7,264
Table 1.  Estimated parameters for the non-strain-specific model fit to the Carenet-NCSF data.
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Figure 3. Validation of non-strain-specific model against hospitalization data from Gasthuisberg 
University Hospital (GUH) in Leuven, Belgium. (a) The number of weekly RVGE hospitalizations at GUH 
is plotted in blue, while the models fit to the Carenet-NCSF data then scaled by estimating the reporting 
fraction are plotted in grey. The black dashed line represents the vaccination coverage in Belgium. (b) The age 
distribution of RVGE patients at GUH (blue) and the mean age distribution predicted by the models (grey) 
prior to vaccine introduction (March 1999-June 2006). The black error bars represent the range of the fitted 
models. (c) The age distribution of RVGE patients at GUH (blue) and predicted by the fitted models (grey) 
following vaccine introduction (July 2006-June 2013).
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attributed at least in part to the pressures imposed by large-scale vaccination. While vaccine effectiveness has been 
shown to be similarly high against all the circulating rotavirus genotypes, consistent with our model estimates, 
slight differences in homotypic versus heterotypic immunity against second infection can explain both the observed 
cycling of genotypes as well as the post-vaccination changes in the genotype distribution. Overall, however, the 
incidence of hospitalization due to RVGE is expected to remain low with continued vaccination.
We used a hierarchy of models, beginning with a simplified model that does not distinguish between the dif-
ferent genotypes of rotavirus (non-strain-specific model), which we showed could explain the observed impact of 
vaccination on the size and timing of peaks of rotavirus hospitalizations in Belgium, as well as the age distribution 
of hospitalized cases. We validated this model by showing that it could also explain the observed number and age 
distribution of RVGE hospitalizations at GUH in Leuven from March 1999 to June 2013. However, the models 
had a tendency to slightly underestimate the proportion of 6–15 month old patients and slightly overestimate the 
proportion of patients < 2 months of age and older children and adults post-vaccination. This may be due to our 
assumptions of homogeneous mixing and/or exponential waning of maternal immunity, while the discrepancy 
between the observed and model-predicted hospitalizations among ≥ 5 year olds could be due to reporting biases 
or model misspecification.
We found that the models had a tendency to predict multi-annual and chaotic dynamics, particularly following 
vaccine introduction. This has also been exhibited by other rotavirus models34. Under certain parameter com-
binations, the reduction in transmission associated with large-scale vaccination could lead to a period of years 
in which very few infections occurred, followed by larger outbreaks. While small annual outbreaks of rotavirus 
have been occurring in Belgium since vaccine introduction in 2006, the United States has been exhibiting bien-
nial post-vaccination epidemics5. Belgium is a small country surrounded by countries that have yet to introduce 
rotavirus vaccination into their routine immunization schedules (at least until recently). It is possible that the 
transmission pressure exerted by the surrounding countries has had a stabilizing influence on the post-vaccination 
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Figure 4. Distribution of rotavirus genotypes pre- and post-vaccination. (a) Number of rotavirus 
hospitalizations per week by genotype (G1—blue, G2—green, non-G1 P[8]—red) at GUH in Leuven, Belgium 
from September 1999 to June 2013. Overall vaccine coverage is indicated by the dashed black line, while the 
light grey line indicates coverage with the Rotarix vaccine (RV1) and the dark grey line represents coverage 
with RotaTeq (RV5). (b) Genotype distribution by year (July to June) from 1999/2000 to 2012/13. The dotted 
black line indicates the year of vaccine introduction. (c) Average genotype distribution over the seven seasons 
pre- (left) and post-vaccine introduction (middle) for RVGE hospitalizations at GUH in Leuven and for the 
Rotavirus Surveillance Network Belgium (right) from September 2007 to December 2012. The total number of 
typed samples (n) is listed under each pie.
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dynamics of rotavirus in Belgium, leading to annual epidemics and the continued circulation of G1P[8] strains. 
Likewise, it has been hypothesized that rotavirus vaccination in Belgium and other neighbouring countries may 
have contributed to the exceptionally low rotavirus incidence in the Netherlands (which has yet to introduce 
vaccination) in 2013/1435. Our model predicts that G1P[8] strains could be essentially eliminated from Belgium 
in the near future if vaccination were to continue at current levels. However, we did not account for possible 
re-introduction of G1P[8] strains from surrounding countries, nor did we account for within-genotype evolution, 
which may lead to selection for G1P[8] strains that escape homotypic immunity from the vaccine strain36. G1P[8] 
continued to be the predominant genotype observed in France, the United Kingdom, and other western European 
countries between 2007–201337.
The predominance of G2P[4] and other fully heterotypic genotypes (e.g. G8P[4]) has also been observed in other 
countries that have introduced the Rotarix vaccine, including Austria, Brazil, and some Australian states20,25–27,37–39. 
In Brazil, G2P[4] was the predominant genotype from 2006–2011, with prevalence ≥ 50% in all years except 2009, 
while G1P[8] has been relatively rare18,27. Furthermore, another fully heterotypic genotype (G8P[4]) emerged in 
Northeast Brazil in 201239. However, a high prevalence of G2P[4] strains was also observed in other South and 
Central American countries without an established rotavirus vaccination program around the same time38,40. While 
it is not unusual for G2P[4] to be the predominant genotype for a year or two in the absence of vaccination, our 
analysis suggests that vaccination may have contributed to its continued high relative prevalence in Belgium over 
the seven years since vaccine introduction.
Our use of semi-nested models, beginning with the non-strain-specific model, then extending it to differenti-
ate among the five major rotavirus genotypes, was necessary because having information on the age distribution 
of cases is essential for informing estimates of the basic reproductive number, R0, but including age structure in 
the strain-specific model considerably increases the computational burden, making the model fitting process too 
time-consuming. The range of R0 estimates from the fitted models were similar to those generated by different 
models fit to pre-vaccination data from England and Wales41. Various models have assumed either no complete 
immunity following infection or temporary immunity lasting ≤ 1 year. However, in preliminary analyses, we noted 
that a longer duration of immunity (in the range of 6–12 months) was necessary to explain the observed cycling 
of genotypes in the strain-specific model.
We had to make a number of simplifying assumptions to limit the number of estimated parameters to an 
identifiable subset. In particular, we assumed that the infectiousness and severity of second infections caused by 
homotypic versus heterotypic strains was proportional to the relative risk of infection, and that the non-G1 P[8] 
strains were equally transmissible. Furthermore, we assumed that the duration of complete immunity following 
vaccination was the same as following natural infection; thus, we assumed some partial waning of vaccine-induced 
immunity, but did not attempt to estimate its duration, as others have done32,34.
It is difficult for the model to capture the exact genotype distributions through time because they are subject to 
stochastic variation as well as cyclical fluctuations. Therefore, we focused our efforts on being able to capture the 
average genotype pattern over the seven years before and six years after vaccine introduction (which is approxi-
mately equal to the multi-annual period of oscillations31), as well as the overall number of RVGE hospitalizations 
by week. We have shown previously that small amounts of stochastic variation (by allowing for fadeout and 
reintroduction of genotype-specific infections) helped to reproduce some of the observed short-term patterns, 
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Figure 5. Posterior distribution of parameters estimated for the strain-specific model. Distribution of 
parameter estimates for (a) the relative risk of second infection with a homotypic strain (σHO, blue), partially 
heterotypic strain (σPH, red), or fully heterotypic strain (σHE, green) compared to the risk of first infection; 
(b) the relative infectiousness of non-G1 P[8] strains (r1, red) and G2 strains (r2, green) compared to G1 strains; 
(c) proportion of vaccinees who seroconvert and thus receive any benefit of vaccination with RV1 (sRV1, purple) 
or RV5 (sRV5, pink), and the proportion of vaccinees who receive broadly heterotypic protection equivalent to 
two natural infections (ξ, grey); and (d) the reporting fraction (hG, black) for moderate-to-severe RVGE cases in 
Belgium to be hospitalized and G-typed at GUH.
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but the average long-term patterns remained qualitatively the same. These stochastic effects could help to explain 
why G9 strains were more prevalent than G3 and G4 strains in our data from Leuven. Furthermore, evidence 
suggests that G9P[8] strains have emerged more recently than the other common rotavirus genotypes42. While 
we attempted to account for this by introducing G9 infections part way through the burn-in period in our model 
(based on estimates of the time to most recent common ancestor), the precise timing of introduction into the local 
population is difficult to determine.
Nevertheless, we believe our analysis is robust. The estimated variation in homotypic versus heterotypic immu-
nity can help to explain the observed changes in the distribution of rotavirus genotypes in Belgium, where vac-
cination has been occurring primarily with the monovalent Rotarix vaccine since 2006. Furthermore, our fitted 
model can be used to predict long-term trends in the genotype distribution and explore potential scenarios related 
to vaccination policy. We believe our models are generalizable to other high-income countries as well, although 
we expect there will be slight differences in the transmission rate of rotavirus from country to country41,43,44. Our 
finding that vaccination is estimated to provide broadly heterotypic immunity suggests that the greater diversity 
of rotavirus genotypes typical of developing countries is likely not the primary reason for the reduce vaccine effi-
cacy observed in low-income settings, consistent with observations from clinical trials and vaccine effectiveness 
studies45–48. Models that take into account the apparent differences in natural and vaccine-induced immunity 
between developed and developing countries are needed to better understand rotavirus dynamics and the impact 
of vaccination in low-income settings.
Materials and Methods
Data sources. We utilized national and local-level data to assess the epidemiological impact of rotavirus vac-
cination in Belgium. At the national level, data were obtained on the weekly number of hospitalized patients with 
a rotavirus diagnosis from July 2004 to June 2012 from members of the National Alliance of Christian Sickness 
Funds (NCSF) through the Carenet database. Carenet is designed for the exchange of information about hospi-
talizations between hospitals and all health insurance companies in Belgium through an electronic system. From 
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Figure 6. Model-predicted impact of vaccination on the incidence and genotype distribution of rotavirus 
in Belgium. (a) Number of typed rotavirus hospitalizations at GUH in Leuven (blue) and model-predicted 
number of rotavirus hospitalizations for 10 randomly sampled parameter sets from the posterior distribution 
(light grey) and the best-fit parameter set (dark grey). (b) Observed genotype distribution at GUH in Leuven 
from September 1999 to June 2006 and model-predicted pre-vaccination genotype distribution for 10 randomly 
sampled parameter sets and the best-fit model. (c) Observed genotype distribution from the Rotavirus 
Surveillance Network Belgium from September 2007 to December 2012 and model-predicted post-vaccination 
genotype distribution for 10 randomly selected parameter sets and the best-fit model.
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Carenet, information was obtained from the members of only one health insurance company (NCSF), which is 
however the largest—it provides health insurance for approximately 42% of the Belgian population. Data on any 
patient for which the diagnosis contained one of the following search strings were included: ‘rota’ or ICD-9-CM 
code ‘008.61’ or ICD-10 code ‘A08.0’. A medical clinician searched the diagnostic fields of the retrieved records 
manually and selected the ones for which rotavirus was likely the main reason for hospitalization. The age of the 
patients was available for 6-month age groups from 0 to 2 years of age, 1-year age groups from 2 to 5 years of age, 
a 5–10 year old age group, and ≥ 10 years of age. All data extractions and associated analyses related to NCSF were 
performed at the Medical Management Department of the NCSF under the supervision of the Chief Medical 
Officer. The other research partners received no personally identifiable information (including small cells) from 
NCSF. We also corrected for the changing coverage of NCSF and the Carenet database over time: the proportion 
of the Belgian population belonging to NCSF decreased slightly between 2004 and 2012 (Fig. 1a), whereas during 
this time, coverage of the Carenet database increased from only 7% of hospital beds in Belgium in January 2004 to 
22% by July 2004 to nearly 100% of hospital beds by 2009 (Fig. 1a). Model output was multiplied by the propor-
tion of the population belonging to NCSF and the proportion of hospital beds covered by the Carenet database 
when fitting the model to the observed data.
At the local level, we had data on genotype-specific hospitalizations for RVGE among patients presenting to the 
Gasthuisberg University Hospital (GUH) in Leuven, Belgium. The incidence of hospitalized RVGE cases at GUH 
has been recorded since January 1981, and rotavirus positive samples have been G-typed since September 1999 and 
G/P-typed since 200328,49,50. Prior to 1993, only data on the total monthly number of hospitalization was available. 
We extracted the data available from January 1993 through June 2013 and aggregated the number of hospitalized 
RVGE cases according to the week of admission, age of patient (in 2-month age groups from 0–24 months, 1-year 
age groups from 2 to 4 years, and ≥ 5 years of age), and genotype (G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], other).
We also had post-vaccination data from the Rotavirus Surveillance Network Belgium (RSNB) from September 
2007 to June 2012. This network receives rotavirus positive stool samples (sent on a voluntary basis) from hospitals, 
diagnostic centres, and individual paediatricians throughout Belgium. Under the framework of this network, a total 
of 2,169 samples were genotyped between September 2007 and June 2012 (≈ 400–600 samples per rotavirus season).
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Figure 7. Model-predicted patterns of rotavirus incidence and annual genotype distributions. Predicted 
number of rotavirus hospitalizations per week in Belgium from January 1999 to December 2023 (left) and 
annual genotype distributions predicted by the model (right) are shown for the following scenarios: (a) best-
fit model predictions given the current level of vaccine coverage; (b) the predicted incidence in the absence 
of vaccination; (c) vaccination at current levels, then no vaccination beginning in July 2015; (d) vaccination 
at current levels, then increasing to 100% coverage with two doses beginning in July 2015; (e) vaccination at 
current levels, but with 90% of vaccinated infants receiving RotaTeq and 10% receiving Rotarix beginning in 
July 2015. The dashed yellow lines in the plots of the annual genotype distribution represent the year of vaccine 
introduction, while the solid yellow lines represents July 2015. The colours correspond to the G-types as in 
previous figures (blue: G1, green: G2, red: G3; light blue: G4; purple: G9).
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To assess changes in vaccine coverage, we used data on (1) sales of the Rotarix and RotaTeq vaccines in Belgium 
from GSK and Sanofi Pasteur MSD, and (2) reimbursements for rotavirus vaccines from the Inter Mutualistic 
Agency (IMA-AIM) (for details, see33). Since Belgium did not begin reimbursing individuals for rotavirus vac-
cines until October 2006, we used the sales data to inform the vaccination coverage rate up until February 2007 
(Fig. S1). Sales of RotaTeq in Belgium did not begin until after February 2007. We used the IMA-AIM data to 
inform the coverage estimates from February 2007 to December 2012, although the two data sources were largely 
in agreement for 2007–2009 (Fig. S1). We calculated the vaccination coverage by first smoothing the data on the 
number of infants vaccinated per week by calculating a 5-week moving average. We then divided the number of 
children vaccinated with at least one dose in week w by the number of births in week w-8, which was interpolated 
from data on monthly births in Belgium (http://ec.europa.eu/eurostat/data/database). To calculate coverage with 
two/three doses (Rotarix/RotaTeq), we likewise divided the number of fully vaccinated children by the number 
of births in week w-12. We assumed coverage in January-June 2013 remained at its most recently observed level 
(from December 2012).
Description of the models. We used two SIR-like compartmental models for the transmission dynamics 
of rotavirus to describe the incidence of RVGE—a simplified model in which we do not distinguish among the 
possible genotypes causing infection (non-strain-specific model) and a more complex model in which we dif-
ferentiate between infection (and previous infection) with five different rotavirus strains, representing the five 
major rotavirus genotypes (strain-specific model) (Fig. 2). Both models have been described previously31,41,44, 
although we made some minor modifications as described below. More details can be found in the Supplementary 
Methods.
Briefly, both models assume that individuals are born with maternal immunity (M) (which provides equal 
protection against all rotavirus strains) that wanes after a mean duration of 1/ωM = 13 weeks51, leaving the infant 
susceptible to a first rotavirus infection (S0). For the non-strain-specific model (Fig. 2a), we assume first infection 
(with any rotavirus genotype) occurs at a rate λ(t). Infected individuals (I1) are infectious for an average of 1/γ1 = 1 
week52,53, after which we assume they are temporarily immune to reinfection (R1) for a period of 1/ω weeks (esti-
mated). Following this period of temporary immunity, the individual becomes susceptible to a second infection 
(S1), which occurs at a reduced rate σ1λ(t)54. Second infections (I2) are assumed to be less infectious (ρ2 = 0.5)55,56, 
of shorter duration (1/γ2 = 0.5 week)57–59, and less likely to result in severe RVGE compared to first infections54. 
Again, infectious individuals recover and are temporarily immune to reinfection (R2). Once this immunity wanes, 
individuals become susceptible to third (and subsequent) infection (SA), which occur at a further reduced rate 
σ2λ(t)54. We assume that these subsequent infections (IA) are only mildly symptomatic (i.e. are not associated 
with severe RVGE (D) and hence are not reported in our datasets)54 and are less infectious (ρA, estimated) and of 
shorter duration (1/γ2 = 0.5 week) compared to first infections. They are again followed by a period of temporary 
immunity (RA); here, we make the simplifying assumption that this immunity wanes at the same rate ω as estimated 
previously, and individuals return to the SA state.
For the strain-specific model (Fig. 2b), we differentiate between first infection with genotype g = 1 to 5 (where 
g = 1 corresponds to G1P[8], g = 2 corresponds to G2P[4], g = 3 corresponds to G3P[8], g = 4 corresponds to 
G4P[8], and g = 5 corresponds to G9P[8]). Fully susceptible individuals (S0) are infected with genotype g at a rate 
λg(t) and enter infected state IP,g and remain infectious for an average of 1/γ1 = 1 week. Again, we assume infection 
is followed by a short period of temporary immunity against all strains (Rg), which wanes at a rate ω, leaving the 
individual susceptible to second infection (Sg). We keep track of the genotype g causing first infection because 
we need to differentiate between second infection occurring with the same genotype (at a rate σHOλg(t)), versus 
a partially heterotypic (at a rate σPHλj≠g(t)) or fully heterotypic genotype (at a rate σPHλj≠g(t)). We assume that 
both the relative infectiousness and severity of second infections with a homotypic (IHO,g) versus partially or fully 
heterotypic genotype (IHE,g) are proportional to σHO, σPH, and σHE, respectively, but that all second infections have 
the same duration of infectiousness, 1/γ2 = 0.5 week. This reduces the number of free parameters to be estimated 
to only those in which we are most interested and have limited data to inform. Following infection with any two 
genotypes, we assume that individuals develop a broad cross-protective immunity to all genotypes31,60. As in 
the non-strain-specific model, individuals are temporarily immune to reinfection (RA), then become susceptible 
to subsequent infections at a reduced rate σ2λg(t). Subsequent infections with genotype g are again only mildly 
symptomatic and shorter and less infectious compared to first infections. Thus, again we assume that only first and 
second infections can result in moderate-to-severe RVGE with genotype g (Dg). The proportion of first infections 
that result in severe RVGE was again assumed to be d1 = 0.13 for all genotypes54, while the proportion of second 
infections resulting in moderate-to-severe RVGE was assumed to vary for homotypic versus heterotypic strains 
with a (weighted) mean equal to d2, such that d2,HO = d2σHO/σ2, d2,HE = d2σHE/σ2, and d2,PH = d2σPH/σ2.
The force of infection with genotype g at time t in weeks (λg(t)) is given by:
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where β0,g is the baseline transmission parameter for genotype g, b is the amplitude of seasonality in the transmis-
sion rate, and φ is the seasonal offset parameter (i.e. timing of peak transmission, in weeks). We assume that the 
transmissibility of the non-G1 P[8] strains is reduced by a factor r1 and the transmissibility of G2P[4] strains is 
reduced by r2 relative to G1P[8], such that β0,3 = β0,4 = β0,5 = r1β0,1 and β0,2 = r2β0,1. This was necessary to explain 
why G1P[8] was the predominant genotype prior to vaccine introduction, as described previously31.
Note that the non-strain-specific model is nested within the strain-specific model; however, we incorporate age 
structure in the non-strain-specific model but not the strain-specific model. Given the same age structure, both 
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models should yield the same overall dynamics when r1 = r2 = 1 and σHO = σPH = σHE = 0.62. Thus, the weighted 
average of σHO, σPH, and σHE should be approximately equal to σ1 = 0.62; however, we do not know the weights, 
which vary with time and correspond to the likelihood of being exposed to someone who is infectious with a 
homotypic versus partially or fully heterotypic genotype.
Modeling vaccination. We assume that a fraction sRV1 and sRV5 seroconvert following vaccination with 
Rotarix and RotaTeq, respectively. In the non-strain-specific model, we assume that one dose of vaccine confers 
immunity comparable to one natural infection, thereby moving individuals from the M and S0 compartments 
into the R1 compartment (Fig. 2a). Vaccination occurs upon aging into the 2-month age class (first dose) and 
4-month age class (second dose). A second (and third) dose of vaccine confers additional immunity comparable 
to a second natural infection in a fraction ξ of fully vaccinated individuals, thereby moving individuals from the 
R1 or S1 state into the R2 state (Fig. 2a).
In the strain-specific model, we model vaccination with Rotarix and RotaTeq separately. Upon birth (since we 
do not include age structure), vaccinated individuals enter either the VR,RV1 or VR,RV5 compartment, depending 
on the vaccine coverage (Fig. 2b). A fraction ξ who is fully vaccinated with either vaccine can develop a broadly 
heterotypic immunity (comparable to two natural infections) and enter the RA state. We assume a fraction sRV1 and 
sRV5 who seroconverted following vaccination (estimated, see Table 2) are temporarily immune, with the duration of 
immunity comparable to that following natural infection (1/ω). Once this immunity wanes, vaccinated individuals 
are susceptible to infection (VS,RV1 or VS,RV5), but at a reduced rate depending on the type of immunity conferred by 
the vaccine. We assume that the RV1 vaccine confers homotypic immunity against G1P[8], heterotypic immunity 
against G2P[4], and partially heterotypic immunity against the non-G1 P[8] strains, whereas for simplicity we 
assume that RV5 confers homotypic immunity against all five strains (Fig. 2b).
We can calculate the modelled vaccine effectiveness as:
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where v2,RV1 and v2,RV5 are the mean proportion of fully vaccinated individuals with Rotarix and RotaTeq vaccines, 
respectively.
Modelling the impact of vaccination on rotavirus hospitalizations in Belgium. We began by fit-
ting the non-strain-specific age-structured model (Fig. 2a) to data on hospitalizations due to rotavirus from the 
Carenet-NCSF database (Fig. 1a). We generated 10,000 parameter sets for the eight parameters to be estimated, 
sampling from reasonable ranges for each parameter using Latin Hypercube Sampling (LHS) (Table 1). We sim-
ulated the incidence of severe RVGE in Belgium and calculated the log-likelihood of the data given the model, 
assuming that the number of hospitalizations reported in the dataset were Poisson distributed with a mean equal 
to the model-predicted incidence of severe RVGE (Da,w) times a hospitalization/reporting factor (ha, estimated) 
and a correction factor that accounts for changes in the coverage of the Carenet database over time and the pro-
portion of the Belgian population covered by NCSF (c):
( ). ( ), ,~H Poisson ch D 6a w a a w
(see Supplementary Methods). We allowed the reporting factor ha to differ between children < 2 years of age 
and older children and adults, with the reporting factor in 2-year olds equal to the mean of these two reporting 
factors, in order to account for differences in testing and diagnosis rates, since the cost of the rotavirus test is only 
reimbursed for children < 2 years of age in Belgium (since 2004). We assumed homogeneous mixing for simplicity 
and because we did not include age structure in the strain-specific model, since doing so caused the model to run 
prohibitively slowly. We assumed uniform prior distributions for all estimated model parameters over ranges that 
were either uninformative or consistent with previous model estimates41, with the exception of the duration of 
temporary immunity (Table 1). We constrained 1/ω to be between 26 and 52 weeks, since we noted that a longer 
duration of temporary immunity was necessary to reproduce the observed cycling of genotypes in strain-specific 
model.
We then used the 10 parameter sets that yielded the highest posterior probability as initial conditions for a 
simplex search algorithm to identify local maxima in the posterior probability surface. We used “fminsearch” in 
MATLAB v7.14 (MathWorks, Natick, MA) to minimize the negative log posterior probability. Multiple different 
parameter sets provided an approximately equally good fit to the data (Table 1). Since our priority here lies in under-
standing the impact of vaccination on the distribution of rotavirus genotypes, we proceeded using the parameter 
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set yielding the highest posterior probability for the strain-specific model, then examined the sensitivity of our 
conclusions to this choice (see Supplementary Methods).
We validated the non-strain-specific model by comparing the fitted models to the hospitalization data from 
GUH in Leuven, Belgium. The only parameter we allowed to vary was the reporting rate for < 2 year olds (since the 
population who seek care at GUH is some unknown fraction of the total Belgian population), which we estimated 
by fitting the model output to the GUH data from March 1993 to December 2013.
Modelling the impact of vaccination on the distribution of rotavirus genotypes. We identified 
nine key parameters to be estimated for the strain-specific model (Fig. 2b): the relative infectiousness of the 
non-G1 P[8] strains compared to G1P[8] (r1); the relative infectiousness of G2P[4] compared to G1P[8] (r2); the 
relative risk of second infection with a homotypic strain (same G- and P-type as the strain causing first infection) 
(σHO); the relative risk of second infection with a partially heterotypic strain (different G-type, same P-type) (σPH); 
the relative risk of second infection with a fully heterotypic strain (different G- and P-type) (σHE); the proportion 
of fully vaccinated individuals who develop a broadly heterotypic immune response (ξ); the proportion of those 
vaccinated with at least one dose of RV1 who seroconvert and therefore receive any protection (sRV1); the pro-
portion of those vaccinated with at least one dose of RV5 who seroconvert (sRV5); and the reporting fraction for 
severe RVGE cases presenting to GUH (hG). We assumed uniform prior distributions for all parameters with the 
exception of sRV1 and sRV5, for which we fitted beta prior distributions to the mean and variance of the rate of sero-
conversion to each vaccine in low child mortality countries reported in a recent meta-analysis (Supplementary 
Table S1)61.
We started by generating 100,000 parameter sets by sampling from reasonable parameter ranges for the nine 
parameters to be estimated using LHS (Supplementary Table S1; see Supplementary Methods). We then simulated 
the strain-specific model under each of the sampled set of parameters and evaluated the ability of the model to 
reproduce three key features of the data: (1) the observed weekly time series of RVGE hospitalizations at GUH 
from September 2007-June 2012; (2) the pre-vaccination distribution of the five common genotypes among GUH 
patients; and (3) the post-vaccination genotype distribution for the RSNB. We again assumed that the weekly num-
ber of RVGE cases as GUH was Poisson-distributed with a mean equal to the model-predicted incidence of severe 
infection times the reporting fraction hG. To calculate the likelihood contribution of the pre- and post-vaccination 
genotype distributions, we assumed the observed total number of infections with each genotype followed a multi-
nomial distribution with probabilities given by the model-predicted genotype distribution. We scaled each of these 
components such that they contributed approximately equally to the overall likelihood in order to ensure that the 
model was able to replicate all three features of the data (see Supplementary Methods).
We used the 10 parameter sets with the highest posterior probability to initialize a simplex search for the best-fit 
parameters for the strain-specific model, but again identified multiple parameter sets with approximately equal 
support (see Supplementary Methods; Supplementary Table S2). We therefore adopted an approach in which we 
used importance sampling to approximate the posterior distribution of the parameters of interest for the 
strain-specific model, f(θS). For our sampling distribution, g(θS), we used a multivariate normal distribution on 
the logit scale, with a mean equal to logit θ( )S , where θS  corresponds to the parameter set with the highest posterior 
probability identified from the simplex search, and variance equal to two times the variance-covariance matrix of 
the logit-transformed top 100 parameter sets. We generated N = 100,000 samples from g(θS) and calculated the 
log-likelihood of the model under each of the parameter sets. We then weighted each of parameter set by:
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We then resampled (with replacement) from g(θS) according to these weights to generate the posterior distri-
bution and calculated the mean of θS as follows:
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The 95% credible interval (CI) for θS was estimated from the 2.5th and 97.5th percentiles of the posterior 
distribution.
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